Nisa Investment Advisors
DSGN icon

Nisa Investment Advisors’s Design Therapeutics DSGN Stock Holding History

Nisa Investment Advisors’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$158K Buy
14,824
+3,000
+25% +$30.4K ﹤0.01% 1286
2025
Q4 		$111K Hold
11,824
– – ﹤0.01% 1399
2025
Q3 		$89K Hold
11,824
– – ﹤0.01% 1468
2025
Q2 		$39.8K Sell
11,824
-92
-0.8% -$344 ﹤0.01% 1655
2025
Q1 		$46K Buy
11,916
+61
+0.5% +$291 ﹤0.01% 1613
2024
Q4 		$73.1K Sell
11,855
-50
-0.4% -$289 ﹤0.01% 1563
2024
Q3 		$64K Buy
11,905
+50
+0.4% +$235 ﹤0.01% 1578
2024
Q2 		$39.7K Buy
11,855
+295
+3% +$1.15K ﹤0.01% 1731
2024
Q1 		$46.6K Hold
11,560
– – ﹤0.01% 1672
2023
Q4 		$30.6K Buy
11,560
+11,530
+38,433% +$26.4K ﹤0.01% 1752
2023
Q3 		$71 Buy
+30
New +$140 ﹤0.01% 2758
2023
Q2 		– Sell
-17
Closed – – 2817
2023
Q1 		$0 Buy
+17
New +$127 ﹤0.01% 2570
2022
Q4 		– Sell
-34
Closed -$1K – 2611
2022
Q3 		$1K Buy
+34
New +$677 ﹤0.01% 2411

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Nisa Investment Advisors's DSGN Position: Q1 2026 in Review

Nisa Investment Advisors increased its Design Therapeutics (DSGN) stake by 25% in Q1 2026, buying an estimated $30.4K and bringing the position to 14,824 shares worth $158K. The position accounts for ﹤0.01% of the portfolio, ranked #1286.

Nisa Investment Advisors first reported a position in DSGN in Q3 2022 and has held it in 13 quarters since. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Nisa Investment Advisors held 14,824 shares of Design Therapeutics worth $158K as of Q1 2026.
  • Nisa Investment Advisors bought 3,000 Design Therapeutics shares in Q1 2026, an estimated $30.4K.
  • Design Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #1286 holding.
  • Nisa Investment Advisors first reported a position in Design Therapeutics in Q3 2022 and has held it in 13 quarters since.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.